Delivery of intracellular-acting biologics in Pro-apoptotic therapies

Current Pharmaceutical Design

Volumn 17, Issue 3, 2011, Pages 293-319

  Li, Hongmei ^a   Nelson, Chris E ^a   Evans, Brian C ^a   Duvall, Craig L ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Apoptosis; Biomacromolecular drug; Delivery barriers; Endosome escape; Intracellular delivery; Peptide drug; RNA interference; SiRNA

Indexed keywords

AMINO ACID; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DEOXYCYTIDINE KINASE; DIATOS PEPTIDE VECTOR 1047; DIATOS PEPTIDE VECTOR 15; DIATOS PEPTIDE VECTOR 15B; DIATOS PEPTIDE VECTOR 3; DIATOS PEPTIDE VECTOR 6; DIATOS PEPTIDE VECTOR 7; DIATOS PEPTIDE VECTOR 7B; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FIBROBLAST GROWTH FACTOR 1; GALANIN; MICRORNA; NUCLEIC ACID; OLIGODEOXYNUCLEOTIDE; PENETRATIN; PEPTIDE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR ENDOTHELIAL CADHERIN;

AMINO ACID SEQUENCE; APOPTOSIS; CARCINOGENESIS; CELL MEMBRANE; DROSOPHILA; DRUG TARGETING; ELECTROPORATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; IONTOPHORESIS; LASER; NONHUMAN; ONCOGENE; PHOTOCHEMICAL INTERNALIZATION; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; VIRUS ENVELOPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; MACROMOLECULAR SUBSTANCES; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 79958241186     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795049642     Document Type: Review

References (351)

1. Fire A, Xu SQ, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabdit is elegans. Nature 1998; 391: 806-811.
2. Reichert JM, Valge-Archer VE. Development trends formonoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6: 349-356.
3. Dimitrov DS, Marks JD. Therapeutic Antibodies: Current State andFuture Trends - Is a Paradigm Change Coming Soon? Methods Mol Biol. 2009; 525: pp. 1-27.
4. Sternberg CN, Dumez H, Van Poppel H, et al. Docetaxel plusoblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTCmulticenter, randomized phase II study in patients with castrationresistantprostate cancer. Annals of Oncology 2009; 20: 1264-1269.
5. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy inpatients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18:1812-1823.
6. Pro B, Leber B, Smith M, et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, incombination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 2008; 143: 355-360.
7. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense(oblimersen sodium) plus dacarbazine in patients with advancedmelanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738-4745.
8. O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial offludarabine plus cyclophosphamide with or without oblimersensodium (Bcl-2 antisense) in patients with relapsed or refractorychronic lymphocytic leukemia. J Clin Oncol 2007; 25: 1114-1120.
9. Raab R, Sparano JA, Ocean AJ, et al. A Phase I Trial ofOblimersen Sodium in Combination With Cisplatin and 5-Fluorouracil in Patients With Advanced Esophageal,Gastroesophageal Junction, and Gastric Carcinoma. American J Clinical Oncology; 33: 61-65.
10. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A Basic Biological Phenomenon with Wide ranging Implications in Tissue Kinetics. BrJ Cancer 1972; 26: 239-257.
11. Wilson TR, Johnston PG, Longley DB. Anti-apoptotic mechanismsof drug resistance in cancer. Curr Cancer Drug Targets 2009; 9:307-319.
12. Kolesnick RN, Kronke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol 1998; 60: 643-665.
13. Asakura T, Sawai T, Hashidume Y, Ohkawa Y, Yokoyama S,Ohkawa K. Caspase-3 activation during apoptosis caused byglutathione-doxorubicin conjugate. Br J Cancer 1999; 80: 711-715.
14. Mesner PW, Jr., Budihardjo, II, Kaufmann SH. Chemo therapy-inducedapoptosis. Adv Pharmacol 1997; 41: 461-499.
15. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-1316.
16. Cohen GM. Caspases: the executioners of apoptosis. Biochem. J.1997; 326: 1-16.
17. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cellsurvival. Science 1998; 281: 1322-1326.
18. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancerdevelopment and therapy. Oncogene 2007; 26: 1324-1337.
19. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307-315.
20. Ashkenazi A, Dixit VM. Death receptors: signaling andmodulation. Science 1998; 281: 1305-1308.
21. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, anovel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-512.
22. Chang HY, Nishitoh H, Yang X, Ichijo H, Baltimore D. Activationof apoptosis signal-regulating kinase 1 (ASK1) by the adapterprotein Daxx. Science 1998; 281: 1860-1863.
23. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL(APO-2L) apoptosis systems. Exp Cell Res 2000; 256: 58-66.
24. Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibitoryproteins: regulators of death receptor-mediatedapoptosis. Mol Cell Biol 2001; 21: 8247-8254.
25. Araujo H, Danziger N, Cordier J, Glowinski J, Chneiweiss H. Characterization of PEA-15, a major substrate for protein kinase C in astrocytes. J Biological Chem 1993; 268: 5911-5920.
26. McDermott U, Longley DB, Galligan L, Allen W, Wilson T, Johnston PG. Effect of p53 status and STAT1 on chemotherapy-induced,Fas-mediated apoptosis in colorectal cancer. Cancer Res 2005; 65: 8951-8960.
27. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
28. Longley DB, Wilson TR, McEwan M, et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006; 25: 838-848.
29. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-1130.
30. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life or-death switch. Nat Rev Cancer 2002; 2: 647-656.
31. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-730.
32. Lindsten T, Ross AJ, King A, et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential fornormal development of multiple tissues. Mol Cell 2000; 6: 1389-1399.
33. Muchmore SW, Sattler M, Liang H, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381: 335-341.
34. Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275: 983-986.
35. Chou JJ, Li H, Salvesen GS, Yuan J, Wagner G. Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell 1999;96: 615-624.
36. McDonnell JM, Fushman D, Milliman CL, Korsmeyer SJ, Cowburn D. Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists. Cell 1999;96: 625-634.
37. Richardson A, Kaye SB. Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy. Curr MolPharmacol 2008; 1: 244-254.
38. Chen L, Willis SN, Wei A, et al. Differential targeting ofprosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
39. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856-859.
40. Franke TF, Cantley LC. Apoptosis. A Bad kinase makes good.Nature 1997; 390: 116-117.
41. Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction toantiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
42. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes & Development 1999; 13: 239-252.
43. Liston P, Fong WG, Korneluk RG. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003; 22: 8568-8580.
44. Srinivasula SM, Gupta S, Datta P, et al. Inhibitor of apoptosis proteins are substrates for the mitochondrial serine proteaseOmi/HtrA2. J Biological Chem 2003; 278: 31469-31472.
45. Altieri DC. Survivin and IAP proteins in cell-death mechanisms.Biochem J 2010; 430: 199-205.
46. Yang L, Mashima T, Sato S, et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugatedSmac peptide. Cancer Res 2003; 63: 831-837.
47. Croce CM. Oncogenes and cancer. N Engl J Med 2008; 358: 502-511.
48. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
49. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003; 284: 31-53.
50. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-3167.
51. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30: 193-204.
52. Lin A, Karin M. NF-kappaB in cancer: a marked target. Semin Cancer Biol 2003; 13: 107-14.
53. Burgering BM, Medema RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt isoff duty. J Leukoc Biol 2003; 73: 689-701.
54. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000; 97: 4227-4232.
55. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003; 101: 1535-42.
56. Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
57. Berenson JR, Ma HM, Vescio R. The role of nuclear factor-kappa Bin the biology and treatment of multiple myeloma. Semin Oncol 2001; 28: 626-633.
58. Mitsiades CS, Mitsiades N, Koutsilieris M. The Akt pathway: molecular targets for anti-cancer drug development. Curr CancerDrug Targets 2004; 4: 235-256.
59. Ponzielli R, Katz S, Barsyte-Lovejoy D, Penn LZ. Cancer therapeutics: Targeting the dark side of Myc. European J Cancer 2005; 41: 2485-2501.
60. Napoli C, Lemieux C, Jorgensen R. Introduction of a ChimericChalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans. Plant Cell 1990; 2:279-289.
61. Guo S, Kemphues KJ. Par-1, a Gene Required for Establishing Polarity in C-Elegans Embryos, Encodes a Putative Ser/Thr Kinase That Is Asymmetrically Distributed. Cell 1995; 81: 611-620.
62. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochemical and Biophysical ResearchCommunications 2002; 296: 1000-1004.
63. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directednuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404: 293-296.
64. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
65. Vogl DT, Gewirtz AM. Nucleic Acid Therapies for Cancer Treatment. Humana: Totowa, N.J 2008.
66. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002; 16: 948-958.
67. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for abidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409: 363-366.
68. Elbashir SM, Lendeckel W, Tuschl T. RNA interference ismediated by 21-and 22-nucleotide RNAs. Genes & Development 2001; 15: 188-200.
69. Bouillet P, Cory S, Zhang LC, Strasser A, Adams JM.Degenerative disorders caused by Bcl-2 deficiency prevented byloss of its BH3-only antagonist Bim. Dev Cell 2001; 1: 645-653.
70. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinomais determined by Bcl-2 content. Ann Surg Oncol 1999; 6: 279-285.
71. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperationbetween myc and bcl-2. Nature 1990; 348: 331-333.
72. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ, Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000; 60:6101-6110.
73. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members intumorigenesis. Biochim Biophys Acta 2004; 1644: 229-249.
74. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
75. Tracey L, Perez-Rosado A, Artiga MJ, et al. Expression of the NF-kappaBtargets BCL2 and BIRC5/Survivin characterizes small B-celland aggressive B-cell lymphomas, respectively. J Pathol 2005;206: 123-134.
76. Reed JC, Kitada S, Takayama S, Miyashita T. Regulation ofchemoresistance by the bcl-2 oncoprotein in non-Hodgkin'slymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994; 5 Suppl 1: 61-65.
77. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognosticsignificance of Bcl-2 protein expression and Bcl-2 generearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244-251.
78. Cosulich SC, Worrall V, Hedge PJ, Green S, Clarke PR. Regulation of apoptosis by BH3 domains in a cell-free system. Curr Biol 1997; 7: 913-920.
79. Duvall CL, Convertine AJ, Benoit DSW, Hoffman AS, Stayton PS.Intracellular Delivery of a Proapoptotic Peptide via Conjugation toa RAFT Synthesized Endosomolytic Polymer. MolecularPharmaceutics 2010; 7: 468-476.
80. Al-Taei S, Penning NA, Simpson JC, et al. Intracellular traffic andfate of protein transduction domains HIV-1 TAT peptide andoctaarginine. Implications for their utilization as drug deliveryvectors. Bioconjug Chem 2006; 17: 90-100.
81. Belting M, Sandgren S, Wittrup A. Nuclear delivery ofmacromolecules: barriers and carriers. Adv Drug Deliv Rev 2005;57: 505-527.
82. Flynn CR, Cheung-Flynn J, Smoke CC, et al. Internalization andintracellular trafficking of a PTD-conjugated anti-fibrotic peptide,AZX100, in human dermal keloid fibroblasts. J Pharm Sci 2010;99: 3100-31021.
83. Tokatlian T, Segura T. siRNA applications in nanomedicine. WileyInterdiscip Rev Nanomed Nanobiotechnol 2010; 2: 305-315.
84. Opanasopit P, Nishikawa M, Hashida M. Factors affecting drugand gene delivery: effects of interaction with blood components. Crit Rev Ther Drug Carrier Syst 2002; 19: 191-233.
85. Owens III DE, Peppas NA. Opsonization, biodistribution, andpharmacokinetics of polymeric nanoparticles. International JPharmaceutics 2006; 307: 93-102.
86. Pliquett UF, Gusbeth CA. Perturbation of human skin due toapplication of high voltage. Bioelectrochem 2000; 51: 41-51.
87. Rols MP, Delteil C, Golzio M, Dumond P, Cros S, Teissie J. Invivo electrically mediated protein and gene transfer in murinemelanoma. Nature Biotechnology 1998; 16: 168-171.
88. Cahill K. Cell-penetrating peptides, electroporation and drugdelivery. Iet Systems Biology 2010; 4: 367-78.
89. Banga AK, Prausnitz MR. Assessing the potential of skinelectroporation for the delivery of protein- and gene-based drugs. Trends in Biotechnology 1998; 16: 408-412.
90. Fyrberg A, Lotfi K. Optimization and evaluation of electroporationdelivery of siRNA in the human leukemic CEM cell line. Cytotechnology 2010; 62: 497-507.
91. Huang HA, Wei ZW, Huang YY, et al. An efficient and highthroughputelectroporation microchip applicable for siRNAdelivery. Lab on a Chip 2011; 11: 163-172.
92. Harding CV. Electroporation of Exogenous Antigen into theCytosol for Antigen Processing and Class-I MajorHistocompatibility Complex (Mhc) Presentation - Weak BaseAmines and Hypothermia (18-Degrees-C) Inhibit the Class-I MhcProcessing Pathway. European J Immunology 1992; 22: 1865-1869.
93. Lukas J, Bartek J, Strauss M. Efficient Transfer of Antibodies intoMammalian-Cells by Electroporation. J Immunological Methods 1994; 170: 255-259.
94. Potter H. Electroporation in Biology - Methods, Applications, andInstrumentation. Analytical BioChem 1988; 174: 361-373.
95. Chakrabarti R, Wylie DE, Schuster SM. Transfer of Monoclonal-Antibodies into Mammalian-Cells by Electroporation. J BiologicalChem 1989; 264: 15494-15500.
96. Kigasawa K, Kajimoto K, Hama S, Saito A, Kanamura K, Kogure K. Noninvasive delivery of siRNA into the epidermis byiontophoresis using an atopic dermatitis-like model rat. International J Pharmaceutics 2010; 383: 157-160.
97. Langkjaer L, Brange J, Grodsky GM, Guy RH. Iontophoresis ofmonomeric insulin analogues in vitro: effects of insulin charge andskin pretreatment. J Controlled Release 1998; 51: 47-56.
98. Degim IT, Celebi N. Controlled delivery of peptides and proteins.Current Pharmaceutical Design 2007; 13: 99-117.
99. Kari B. Control of Blood-Glucose Levels in Alloxan-DiabeticRabbits by Iontophoresis of Insulin. Diabetes 1986; 35: 217-221.
100. Hao JS, Li SK, Liu CY, Kao WWY. Electrically assisted deliveryof macromolecules into the corneal epithelium. Experimental EyeResearch 2009; 89: 934-941.
101. Mitragotri S, Kost J. Low frequency sonophoresis: A noninvasivemethod of drug delivery and diagnostics. Biotechnology Progress 2000; 16: 488-492.
102. Fretz MM, Hogset A, Koning GA, Jiskoot W, Storm G. Cytosolicdelivery of liposomally targeted proteins induced by photochemicalinternalization. Pharmaceutical Research 2007; 24: 2040-2047.
103. Berg K, Moan J. Lysosomes as photochemical targets. Int J Cancer 1994; 59: 814-822.
104. Berg K, Dietze A, Kaalhus O, Hogset A. Site-specific drug deliveryby photochemical internalization enhances the antitumor effect ofbleomycin. Clin Cancer Res 2005; 11: 8476-8485.
105. Selbo PK, Sandvig K, Kirveliene V, Berg K. Release of geloninfrom endosomes and lysosomes to cytosol by photochemicalinternalization. Biochim Biophys Acta 2000; 1475: 307-313.
106. Raemdonck K, Naeye B, Hogset A, Demeester J, De Smedt SC.Prolonged gene silencing by combining siRNA nanogels andphotochemical internalization. J Controlled Release 2010; 145:281-288.
107. Lee WR, Pan TL, Wang PW, Zhuo RZ, Huang CM, Fang JY.Erbium:YAG laser enhances transdermal peptide delivery and skinvaccination. J Controlled Release 2008; 128: 200-208.
108. Lee WR, Shen SC, Lai HH, Hu CH, Fang JY. Transdermal drugdelivery enhanced and controlled by erbium:YAG laser: acomparative study of lipophilic and hydrophilic drugs. J Controlled Release 2001; 75: 155-166.
109. Fang JY, Lee WR, Shen SC, Fang YP, Hu CH. Enhancement oftopical 5-aminolaevulinic acid delivery by erbium:YAG laser andmicrodermabrasion: a comparison with iontophoresis andelectroporation. Br J Dermatol 2004; 151: 132-140.
110. Lee WR, Shen SC, Zhuo RZ, Wang KC, Fang JY. Enhancement ofTopical Small Interfering RNA Delivery and Expression by Low-Fluence Erbium: YAG Laser Pretreatment of Skin. Human GeneTherapy 2009; 20: 580-588.
111. Green M, Loewenstein PM. Autonomous Functional Domains ofChemically Synthesized Human Immunodeficiency Virus TatTrans-Activator Protein. Cell 1988; 55: 1179-1188.
112. Frankel AD, Pabo CO. Cellular Uptake of the Tat Protein fromHuman Immunodeficiency Virus. Cell 1988; 55: 1189-1193.
113. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The 3rd Helix ofthe Antennapedia Homeodomain Translocates through Biological-Membranes. J Biological Chem 1994; 269: 10444-10450.
114. El-Sayed A, Futaki S, Harashima H. Delivery of MacromoleculesUsing Arginine-Rich Cell-Penetrating Peptides: Ways to OvercomeE ndosomal Entrapment. Aaps Journal 2009; 11: 13-22.
115. Lopes LB, Flynn C, Komalavilas P, Panitch A, Brophy CM, Seal BL. Inhibition of HSP27 phosphorylation by a cell-permeantMAPKAP Kinase 2 inhibitor. Biochemical and BiophysicalResearch Communications 2009; 382: 535-539.
116. Nishikawa M, Otsuki T, Ota A, et al. Induction of Tumor-specificImmune Response by Gene Transfer of Hsp70-cell-penetratingPeptide Fusion Protein to Tumors in Mice. Molecular Therapy 2010; 18: 421-428.
117. De Coupade C, Fittipaldi A, Chagnas V, et al. Novel humanderivedcell-penetrating peptides for specific subcellular delivery oftherapeutic biomolecules. Biochemical Journal 2005; 390: 407-418.
118. Saalik P, Elmquist A, Hansen M, et al. Protein cargo deliveryproperties of cell-penetrating peptides. A comparative study.Bioconjugate Chem 2004; 15: 1246-1253.
119. Banoczi Z, Gorka-Kereskenyi A, Remenyi J, et al. Synthesis and inVitro Antitumor Effect of Vinblastine Derivative-OligoarginineConjugates. Bioconjugate Chem 2010; 21: 1948-1955.
120. Yu HH, Nakase I, Pujals S, et al. Expressed protein ligation for thepreparation of fusion proteins with cell penetrating peptides forendotoxin removal and intracellular delivery. Biochimica EtBiophysica Acta-Biomembranes 2010; 1798: 2249-2257.
121. Heitz F, Morris MC, Divita G. Twenty years of cell-penetratingpeptides: from molecular mechanisms to therapeutics. British JPharmacology 2009; 157: 195-206.
122. Patel LN, Zaro JL, Shen WC. Cell penetrating peptides:Intracellular pathways and pharmaceutical perspectives. Pharmaceutical Research 2007; 24: 1977-1992.
123. Fuchs SM, Raines RT. Pathway for polyarginine entry intomammalian cell. BioChem 2004; 43: 2438-2444.
124. Raagel H, Saalik P, Pooga M. Peptide-mediated protein delivery-Which pathways are penetrable? Biochimica Et Biophysica Acta-Biomembranes 2010; 1798: 2240-2248.
125. Duvall CL, Convertine AJ, Benoit DS, Hoffman AS, Stayton PS.Intracellular delivery of a proapoptotic peptide via conjugation to aRAFT synthesized endosomolytic polymer. Mol Pharm 2010; 7:468-476.
126. Torchilin VP. Cell penetrating peptide-modified pharmaceuticalnanocarriers for intracellular drug and gene delivery. Biopolymers 2008; 90: 604-610.
127. Convertine AJ, Benoit DSW, Duvall CL, Hoffman AS, Stayton PS.Development of a novel endosomolytic diblock copolymer forsiRNA delivery. J Controlled Release 2009; 133: 221-229.
128. Futaki S, Masui Y, Nakase I, et al. Unique features of a pHsensitivefusogenic peptide that improves the transfectionefficiency of cationic liposomes. J Gene Medicine 2005; 7: 1450-1458.
129. Kyriakides TR, Cheung CY, Murthy N, Bornstein P, Stayton PS,Hoffman AS. pH-sensitive polymers that enhance intracellular drugdelivery in vivo. J Controlled Release 2002; 78: 295-303.
130. Ward B, Seal BL, Brophy CM, Panitch A. Design of a bioactivecell-penetrating peptide: when a transduction domain does morethan transduce. J Peptide Science 2009; 15: 668-674.
131. Holm T, Raagel H, Andaloussi SE, et al. Retro-inversion of certaincell-penetrating peptides causes severe cellular toxicity. BiochimBiophys Acta 2010.
132. Huang S, Liu YW, Jiang Y. [Cell penetrating peptides in cancertherapy]. Sheng Li Ke Xue Jin Zhan 2007; 38: 301-306.
133. Myrberg H, Zhang L, Mae M, Langel U. Design of a tumorhomingcell-penetrating peptide. Bioconjug Chem 2008; 19: 70-75.
134. Bitler BG, Schroeder JA. Anti-cancer therapies that utilize cellpenetrating peptides. Recent Pat Anticancer Drug Discov 2010; 5:99-108.
135. Li W, Nicol F, Szoka FC, Jr. GALA: a designed synthetic pHresponsiveamphipathic peptide with applications in drug and genedelivery. Adv Drug Deliv Rev 2004; 56: 967-985.
136. Top D, de Antueno R, Salsman J, et al. Liposome reconstitution ofa minimal protein-mediated membrane fusion machine. EMBO J 2005; 24: 2980-2988.
137. Van Rossenberg SM, Sliedregt-Bol KM, Meeuwenoord NJ, et al. Targeted lysosome disruptive elements for improvement ofparenchymal liver cell-specific gene delivery. J Biological Chem 2002; 277: 45803-45810.
138. Efremov RG, Nolde DE, Volynsky PE, Chernyavsky AA,Dubovskii PV, Arseniev AS. Factors important for fusogenicactivity of peptides: molecular modeling study of analogs of fusionpeptide of influenza virus hemagglutinin. Febs Letters 1999; 462:205-210.
139. Monsigny M, Roche AC, Midoux P, Mayer R. Glycoconjugates asCarriers for Specific Delivery of Therapeutic Drugs and Genes. Advanced Drug Delivery Reviews 1994; 14: 1-24.
140. Plank C, Oberhauser B, Mechtler K, Koch C, Wagner E. TheInfluence of Endosome-Disruptive Peptides on Gene-TransferUsing Synthetic Virus-Like Gene-Transfer Systems. J BiologicalChem 1994; 269: 12918-12924.
141. Wyman TB, Nicol F, Zelphati O, Scaria PV, Plank C, Szoka FC, Jr.Design, synthesis, and characterization of a cationic peptide thatbinds to nucleic acids and permeabilizes bilayers. BioChem 1997;36: 3008-3017.
142. Turk MJ, Reddy JA, Chmielewski JA, Low PS. Characterization ofa novel pH-sensitive peptide that enhances drug release fromfolate-targeted liposomes at endosomal pHs. Biochim BiophysActa 2002; 1559: 56-68.
143. Niidome T, Takaji K, Urakawa M, et al. Chain length of cationicalpha-helical peptide sufficient for gene delivery into cells. Bioconjug Chem 1999; 10: 773-780.
144. Rittner K, Benavente A, Bompard-Sorlet A, et al. New basicmembrane-destabilizing peptides for plasmid-based gene deliveryin vitro and in vivo. Molecular Therapy 2002; 5: 104-114.
145. Kichler A, Leborgne C, Marz J, Danos O, Bechinger B. Histidinerichamphipathic peptide antibiotics promote efficient delivery ofDNA into mammalian cells. Proc Natl Acad Sci USA 2003; 100:1564-1568.
146. Pillot T, Goethals M, Vanloo B, et al. Fusogenic properties of theC-terminal domain of the Alzheimer beta-amyloid peptide. JBiological Chem 1996; 271: 28757-28765.
147. Ogris M, Carlisle RC, Bettinger T, Seymour LW. Melittin enablesefficient vesicular escape and enhanced nuclear access of nonviralgene delivery vectors. J Biological Chem 2001; 276: 47550-47555.
148. Chen CP, Kim JS, Steenblock E, Liu DJ, Rice KG. Gene transferwith poly-melittin peptides. Bioconjugate Chem 2006; 17: 1057-1062.
149. Marty C, Meylan C, Schott H, Ballmer-Hofer K, Schwendener RA.Enhanced heparan sulfate proteoglycan-mediated uptake of cellpenetratingpeptide-modified liposomes. Cellular and MolecularLife Sciences 2004; 61: 1785-1794.
150. Ayame H, Morimoto N, Akiyoshi K. Self-assembled cationicnanogels for intracellular protein delivery. Bioconjugate Chem 2008; 19: 882-90.
151. Zhao PQ, Wang HJ, Yu M, et al. Paclitaxel-Loaded, Folic-Acid-Targeted and TAT-Peptide-Conjugated Polymeric Liposomes: InVitro and In Vivo Evaluation. Pharmaceutical Research 2010; 27:1914-1926.
152. El-Sayed A, Khalil IA, Kogure K, Futaki S, Harashima H.Octaarginine- and octalysine-modified nanoparticles have differentmodes of endosomal escape. J Biological Chem 2008; 283: 23450-23461.
153. Kuai R, Yuan WM, Qin Y, et al. Efficient Delivery of Payload intoTumor Cells in a Controlled Manner by TAT and ThiolyticCleavable PEG Co-Modified Liposomes. Molecular Pharmaceutics 2010; 7: 1816-1826.
154. Ko YT, Falcao C, Torchilin VP. Cationic Liposomes Loaded withProapoptotic Peptide D-(KLAKLAK)(2) and Bcl-2 AntisenseOligodeoxynucleotide G3139 for Enhanced Anticancer Therapy. Molecular Pharmaceutics 2009; 6: 971-977.
155. Yamada Y, Akita H, Kogure K, Kamiya H, Harashima H. Mitochondrial drug delivery and mitochondrial disease therapy -An approach to liposome-based delivery targeted to mitochondria. Mitochondrion 2007; 7: 63-71.
156. Huang Z, King MR. An immobilized nanoparticle-based platformfor efficient gene knockdown of targeted cells in the circulation. Gene Ther 2009; 16: 1271-1282.
157. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemicleukocyte-directed siRNA delivery revealing cyclin D1 as an antiinflammatorytarget. Science 2008; 319: 627-630.
158. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of thebasic science, rationale, and clinical applications, existing andpotential. Int J Nanomedicine 2006; 1: 297-315.
159. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlanI. Sequence-dependent stimulation of the mammalian innateimmune response by synthetic siRNA. Nat Biotechnol 2005; 23:457-462.
160. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: anupdate review. Curr Drug Deliv 2007; 4: 297-305.
161. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistentin vivo anti-HBV activity of chemically modified siRNAs. NatBiotechnol 2005; 23: 1002-1007.
162. Chen Y, Bathula SR, Li J, Huang L. Multifunctional nanoparticlesdelivering small interfering RNA and doxorubicin overcome drugresistance in cancer. J Biol Chem 2010; 285: 22639-22650.
163. Chen Y, Sen J, Bathula SR, Yang Q, Fittipaldi R, Huang L. Novelcationic lipid that delivers siRNA and enhances therapeutic effectin lung cancer cells. Mol Pharm 2009; 6: 696-705.
164. Mori A. Biochemistry and neurotoxicology of guanidinocompounds. History and recent advances. Pavlov J Biol Sci 1987;22: 85-94.
165. Wartenberg M, Ling FC, Schallenberg M, et al. Down-regulationof intrinsic P-glycoprotein expression in multicellular prostatetumor spheroids by reactive oxygen species. J Biol Chem 2001;276: 17420-17428.
166. Cai Y, Lu J, Miao Z, Lin L, Ding J. Reactive oxygen speciescontribute to cell killing and P-glycoprotein downregulation bysalvicine in multidrug resistant K562/A02 cells. Cancer Biol Ther 2007; 6: 1794-1799.
167. Song WJ, Du JZ, Sun TM, Zhang PZ, Wang J. Gold nanoparticlescapped with polyethyleneimine for enhanced siRNA delivery. Small 2010; 6: 239-246.
168. Derfus AM, Chen AA, Min D-H, Ruoslahti E, Bhatia SN. TargetedQuantum Dot Conjugates for siRNA Delivery. Bioconjugate Chem 2007; 18: 1391-1396.
169. Yezhelyev MV, Qi L, OâRegan RM, Nie S, Gao X. Proton-Sponge Coated Quantum Dots for siRNA Delivery andIntracellular Imaging. J the American Chemical Society 2008; 130:9006-9012.
170. Takeshita F, Minakuchi Y, Nagahara S, et al. Efficient delivery ofsmall interfering RNA to bone-metastatic tumors by usingatelocollagen in vivo. Proc Natl Acad Sci USA 2005; 102: 12177-12182.
171. Takeshita F, Ochiya T. Therapeutic potential of RNA interferenceagainst cancer. Cancer Sci 2006; 97: 689-696.
172. Noh SM, Han SE, Shim G, et al. Tocopheryl oligochitosan-basedself assembling oligomersomes for siRNA delivery. Biomaterials 2011; 32: 849-857.
173. Kong WH, Sung DK, Shim YH, et al. Efficient intracellular siRNAdelivery strategy through rapid and simple two steps mixinginvolving noncovalent post-PEGylation. J Controlled Release 2009; 138: 141-147.
174. Nam HY, McGinn A, Kim PH, Kim SW, Bull DA. Primarycardiomyocyte-targeted bioreducible polymer for efficient genedelivery to the myocardium. Biomaterials 2010; 31: 8081-8087.
175. Christensen LV, Chang CW, Kim WJ, et al. Reducible poly(amidoethylenimine)s designed for triggered intracellular gene delivery. Bioconjug Chem 2006; 17: 1233-1240.
176. Thomas JL, Barton SW, Tirrell DA. Membrane Solubilization by aHydrophobic Polyelectrolyte - Surface-Activity and Membrane-Binding. Biophysical Journal 1994; 67: 1101-1106.
177. Thomas JL, Tirrell DA. Polyelectrolyte-Sensitized Phospholipid-Vesicles. Accounts of Chemical Research 1992; 25: 336-342.
178. Borden KA, Eum KM, Langley KH, Tirrell DA. Interactions ofSynthetic-Polymers with Cell-Membranes + Model MembraneSystems.13. On the Mechanism of Polyelectrolyte-InducedStructural Reorganization in Thin Molecular Films. Macromolecules 1987; 20: 454-456.
179. Lackey CA, Press OW, Hoffman AS, Stayton PS. A biomimeticpH-responsive polymer directs endosomal release and intracellulardelivery of an endocytosed antibody complex. Bioconjugate Chem 2002; 13: 996-1001.
180. Akinc A, Thomas M, Klibanov AM, Langer R. Exploringpolyethylenimine-mediated DNA transfection and the protonsponge hypothesis. J Gene Medicine 2005; 7: 657-663.
181. Lackey CA, Murthy N, Press OW, Tirrell DA, Hoffman AS, Stayton PS. Hemolytic activity of pH-responsive polymerstreptavidinbioconjugates. Bioconjugate Chem 1999; 10: 401-405.
182. Henry SM, El-Sayed MEH, Pirie CM, Hoffman AS, Stayton PS. pH-responsive poly(styrene-alt-maleic anhydride) alkylamidecopolymers for intracellular drug delivery. Biomacromolecules 2006; 7: 2407-2414.
183. Murthy N, Campbell J, Fausto N, Hoffman AS, Stayton PS. Bioinspired pH-responsive polymers for the intracellular deliveryof biomolecular drugs. Bioconjug Chem 2003; 14: 412-419.
184. Murthy N, Campbell J, Fausto N, Hoffman AS, Stayton PS. Designand synthesis of pH-responsive polymeric carriers that targetuptake and enhance the intracellular delivery of oligonucleotides. JControlled Release 2003; 89: 365-374.
185. Foster S, Duvall CL, Crownover EF, Hoffman AS, Stayton PS. Intracellular Delivery of a Protein Antigen with an Endosomal-Releasing Polymer Enhances CD8 T-Cell Production andProphylactic Vaccine Efficacy. Bioconjug Chem.
186. Convertine AJ, Diab C, Prieve M, et al. pH-Responsive PolymericMicelle Carriers for siRNA Drugs. Biomacromolecules; 11: 2904-2911.
187. Behr JP. The proton sponge: a means to enter cells viruses neverthought of. Med Sci 1996; 12: 56-58.
188. Wagner E, Ogris M, Zauner W. Polylysine-based transfectionsystems utilizing receptor-mediated delivery. Adv Drug Deliv Rev 1998; 30: 97-113.
189. Boussif O, Zanta MA, Behr JP. Optimized galenics improve invitro gene transfer with cationic molecules up to 1000-fold. GeneTherapy 1996; 3: 1074-1080.
190. Harada Y, Iwai M, Tanaka S, et al. Highly efficient suicide geneexpression in hepatocellular carcinoma cells by epstein-barr virusbasedplasmid vectors combined with polyamidoamine dendrimer. Cancer Gene Ther 2000; 7: 27-36.
191. Anderson DG, Akinc A, Hossain N, Langer R. Structure/propertystudies of polymeric gene delivery using a library of poly(betaaminoesters). Molecular Therapy 2005; 11: 426-434.
192. Wang CY, Huang L. Polyhistidine Mediates an Acid-DependentFusion of Negatively Charged Liposomes. BioChem 1984; 23:4409-4416.
193. Pichon C, Goncalves C, Midoux P. Histidine-rich peptides andpolymers for nucleic acids delivery. Advanced Drug DeliveryReviews 2001; 53: 75-94.
194. Midoux P, Kichler A, Boutin V, Maurizot JC, Monsigny M. Membrane permeabilization and efficient gene transfer by a peptidecontaining several histidines. Bioconjugate Chem 1998; 9: 260-267.
195. Fischer D, Bieber T, Li Y, Elsasser HP, Kissel T. A novel non-viralvector for DNA delivery based on low molecular weight, branchedpolyethylenimine: effect of molecular weight on transfectionefficiency and cytotoxicity. Pharm Res 1999; 16: 1273-1279.
196. Kunath K, von Harpe A, Fischer D, et al. Low-molecular-weightpolyethylenimine as a non-viral vector for DNA delivery:comparison of physicochemical properties, transfection efficiencyand in vivo distribution with high-molecular-weightpolyethylenimine. J Control Release 2003; 89: 113-125.
197. Turunen MP, Hiltunen MO, Ruponen M, et al. Efficient adventitialgene delivery to rabbit carotid artery with cationic polymer-plasmidcomplexes. Gene Ther 1999; 6: 6-11.
198. Creusat G, Rinaldi AS, Weiss E, et al. Proton sponge trick for pHsensitivedisassembly of polyethylenimine-based siRNA deliverysystems. Bioconjug Chem; 21: 994-1002.
199. Meyer M, Philipp A, Oskuee R, Schmidt C, Wagner E. Breathinglife into polycations: Functionalization with pH-responsiveendosomolytic peptides and polyethylene glycol enables siRNAdelivery. J Am Chem Soc 2008; 130: 3272-3273.
200. Pack DW, Putnam D, Langer R. Design of imidazole-containingendosomolytic biopolymers for gene delivery. Biotechnol Bioeng 2000; 67: 217-23.
201. Putnam D, Gentry CA, Pack DW, Langer R. Polymer-based genedelivery with low cytotoxicity by a unique balance of side-chaintermini. Proc Natl Acad Sci USA 2001; 98: 1200-1205.
202. Beyerle A, Merkel O, Stoeger T, Kissel T. PEGylation affectscytotoxicity and cell-compatibility of poly(ethylene imine) for lungapplication: structure-function relationships. Toxicol ApplPharmacol 2010; 242: 146-154.
203. Lynn DM, Langer R. Degradable poly(beta-amino esters):Synthesis, characterization, and self-assembly with plasmid DNA. Jthe American Chemical Society 2000; 122: 10761-10768.
204. Vandenbroucke RE, De Geest BG, Bonne S, et al. Prolonged genesilencing in hepatoma cells and primary hepatocytes after smallinterfering RNA delivery with biodegradable poly(beta-aminoesters). J Gene Med 2008; 10: 783-794.
205. Burke RS, Pun SH. Extracellular Barriers to in Vivo PEI andPEGylated PEI Polyplex-Mediated Gene Delivery to the Liver. Bioconjugate Chem 2008; 19: 693-704.
206. Xu L, Anchordoquy T. Drug delivery trends in clinical trials andtranslational medicine: Challenges and opportunities in the deliveryof nucleic acid-based therapeutics. J Pharm Sci 2011; 100: 38-52.
207. Yan X, Scherphof GL, Kamps JA. Liposome opsonization. JLiposome Res 2005; 15: 109-139.
208. Li SD, Huang L. Nanoparticles evading the reticuloendothelialsystem: role of the supported bilayer. Biochim Biophys Acta 2009;1788: 2259-2266.
209. Zhang Y, Li H, Sun J, et al. DC-Chol/DOPE cationic liposomes: acomparative study of the influence factors on plasmid pDNA andsiRNA gene delivery. Int J Pharm 2010; 390: 198-207.
210. Naeye B, Raemdonck K, Remaut K, Sproat B, Demeester J, DeSmedt SC. PEGylation of biodegradable dextran nanogels forsiRNA delivery. Eur J Pharm Sci 2010; 40: 342-351.
211. Wang XL, Xu R, Lu ZR. A peptide-targeted delivery system withpH-sensitive amphiphilic cell membrane disruption for efficientreceptor-mediated siRNA delivery. J Controlled Release 2009; 134:207-213.
212. Malek A, Merkel O, Fink L, Czubayko F, Kissel T, Aigner A. Invivo pharmacokinetics, tissue distribution and underlyingmechanisms of various PEI(-PEG)/siRNA complexes. ToxicolAppl Pharmacol 2009; 236: 97-108.
213. Hatakeyama H, Ito E, Akita H, et al. A pH-sensitive fusogenicpeptide facilitates endosomal escape and greatly enhances the genesilencing of siRNA-containing nanoparticles in vitro and in vivo. JControlled Release 2009; 139: 127-132.
214. Gao J, Sun J, Li H, et al. Lyophilized HER2-specific PEGylatedimmunoliposomes for active siRNA gene silencing. Biomaterials 2010; 31: 2655-2664.
215. Li SD, Chen YC, Hackett MJ, Huang L. Tumor-targeted deliveryof siRNA by self-assembled nanoparticles. Mol Ther 2008; 16:163-169.
216. Li SD, Huang L. Stealth nanoparticles: high density but sheddablePEG is a key for tumor targeting. J Controlled Release 2010; 145:178-181.
217. Cao N, Cheng D, Zou S, Ai H, Gao J, Shuai X. The synergisticeffect of hierarchical assemblies of siRNA and chemotherapeuticdrugs co-delivered into hepatic cancer cells. Biomaterials 2010.
218. Lu W, Zhang G, Zhang R, et al. Tumor site-specific silencing ofNF-kappaB p65 by targeted hollow gold nanosphere-mediatedphotothermal transfection. Cancer Research 2010; 70: 3177-3188.
219. Antony AC, Kincade RS, Verma RS, Krishnan SR. Identificationof high affinity folate binding proteins in human erythrocytemembranes. J Clin Invest 1987; 80: 711-723.
220. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML.The transferrin receptor part I: Biology and targeting with cytotoxicantibodies for the treatment of cancer. Clin Immunol 2006; 121:144-158.
221. Gomme PT, McCann KB, Bertolini J. Transferrin: structure,function and potential therapeutic actions. Drug Discov Today 2005; 10: 267-273.
222. Prost AC, Menegaux F, Langlois P, et al. Differential transferrinreceptor density in human colorectal cancer: A potential probe fordiagnosis and therapy. Int J Oncol 1998; 13: 871-875.
223. Bartlett DW, Davis ME. Impact of tumor-specific targeting anddosing schedule on tumor growth inhibition after intravenousadministration of siRNA-containing nanoparticles. BiotechnolBioeng 2008; 99: 975-985.
224. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviraldelivery of small interfering RNA inhibits tumor growth in amurine model of metastatic Ewing's sarcoma. Cancer Research 2005; 65: 8984-8992.
225. Mendonca LS, Firmino F, Moreira JN, Pedroso de Lima MC,Simoes S. Transferrin receptor-targeted liposomes encapsulatinganti-BCR-ABL siRNA or asODN for chronic myeloid leukemiatreatment. Bioconjug Chem 2010; 21: 157-168.
226. Felber AE, Castagner B, Elsabahy M, Deleavey GF, Damha MJ, Leroux JC. siRNA nanocarriers based on methacrylic acidcopolymers. J Controlled Release 2010.
227. Suzuki E, Daniels TR, Helguera G, Penichet ML, Umezawa K,Bonavida B. Inhibition of NF-kappaB and Akt pathways by anantibody-avidin fusion protein sensitizes malignant B-cells tocisplatin-induced apoptosis. Int J Oncol 2010; 36: 1299-1307.
228. Pirollo KF, Zon G, Rait A, et al. Tumor-targetingnanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 2006; 17: 117-124.
229. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of genefunction in somatic mammalian cells using small interfering RNAs. Methods 2002; 26: 199-213.
230. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. NatBiotech 2004; 22: 326-330.
231. Aigner A. Delivery systems for the direct application of siRNAs toinduce RNA interference (RNAi) in vivo. J Biomed Biotechnol2006; 2006: 71659.
232. Aigner A. Gene silencing through RNA interference (RNAi) invivo: strategies based on the direct application of siRNAs. JBiotechnol 2006; 124: 12-25.
233. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and targetindependentangiogenesis suppression by siRNA via TLR3. Nature 2008; 452: 591-7.
234. Jackson AL, Linsley PS. Recognizing and avoiding siRNA offtargeteffects for target identification and therapeutic application. Nat Rev Drug Discov; 9: 57-67.
235. Chorev M, Chaturvedi N, Shavitz R, Goodman M. PartiallyModified Retro-Inverso-Peptides - Novel Modification ofBiologically-Active Peptides. Federation Proceedings 1979; 38:363-373.
236. Taylor JW. The synthesis and study of side-chain lactam-bridgedpeptides. Biopolymers 2002; 66: 49-75.
237. Henchey LK, Jochim AL, Arora PS. Contemporary strategies forthe stabilization of peptides in the alpha-helical conformation. CurrOpin Chem Biol 2008; 12: 692-697.
238. Ghadiri MR, Choi C. Secondary Structure Nucleation in Peptides -Transition-Metal Ion Stabilized Alpha-Helices. J the AmericanChemical Society 1990; 112: 1630-1632.
239. Osapay G, Taylor JW. Multicyclic Polypeptide Model Compounds.2. Synthesis and Conformational Properties of a Highly Alpha-Helical Uncosapeptide Constrained by 3 Side-Chain to Side-ChainLactam Bridges. J the American Chemical Society 1992; 114:6966-6973.
240. Brunel FM, Dawson PE. Synthesis of constrained helical peptidesby thioether ligation: application to analogs of gp41. ChemicalCommunications 2005: 2552-2554.
241. Kritzer JA. STAPLED PEPTIDES Magic bullets in nature'sarsenal. Nature Chemical Biology 2010; 6: 566-567.
242. Sheridan C. Roche backs Aileron's stapled peptides. NatureBiotechnology 2010; 28: 992-1002.
243. Schafmeister CE, Po J, Verdine GL. An all-hydrocarbon crosslinkingsystem for enhancing the helicity and metabolic stability ofpeptides. J the American Chemical Society 2000; 122: 5891-5892.
244. Blackwell HEG, R. H. Highly Efficient Synthesis of CovalentlyCross-Linked Peptide Helices by Ring-Closing Metathesis. Angew.Chem. Int. Ed. 1998; 37: 3281-3284.
245. Walensky LD, Kung AL, Escher I, et al. Activation of apoptosis invivo by a hydrocarbon-stapled BH3 helix. Science 2004; 305:1466-1470.
246. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
247. Yang DC, Elliott RL, Head JF. Gene targets of antisense therapiesin breast cancer. Expert Opin Ther Targets 2002; 6: 375-385.
248. Devi GR. siRNA-based approaches in cancer therapy. Cancer GeneTher 2006; 13: 819-829.
249. Sasi N, Hwang M, Jaboin J, Csiki I, Lu B. Regulated cell deathpathways: New twists in modulation of BCL2 family function. Molecular Cancer Therapeutics 2009; 8: 1421-1429.
250. Futami T, Miyagishi M, Seki M, Taira K. Induction of apoptosis inHeLa cells with siRNA expression vector targeted against bcl-2. Nucleic Acids Res Suppl 2002: 251-252.
251. Yin JQ, Gao J, Shao R, Tian WN, Wang J, Wan Y. siRNA agentsinhibit oncogene expression and attenuate human tumor cellgrowth. J Exp Ther Oncol 2003; 3: 194-204.
252. Poeck H, Besch R, Maihoefer C, et al. 5 '-triphosphate-siRNA:turning gene silencing and Rig-I activation against melanoma. Nature Medicine 2008; 14: 1256-1263.
253. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin)by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAILinducedapoptosis. Cell Death Differ 2004; 11: 915-923.
254. Dasgupta A, Alvarado CS, Xu Z, Findley HW. Expression andfunctional role of inhibitor-of-apoptosis protein livin (BIRC7) inneuroblastoma. Biochem Biophys Res Commun 2010; 400: 53-59.
255. Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for newanticancer interventions. J Cellular and Molecular Medicine 2005;9: 360-372.
256. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrialsurvivin inhibits apoptosis and promotes tumorigenesis. J ClinInvest 2004; 114: 1117-1127.
257. Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis proteinfamily member. J Biol Chem 2001; 276: 3238-3246.
258. Kappler M, Bache M, Bartel F, et al. Knockdown of survivinexpression by small interfering RNA reduces the clonogenicsurvival of human sarcoma cell lines independently of p53. CancerGene Ther 2004; 11: 186-193.
259. Liu JL, Wang Y, Jiang J, et al. Inhibition of survivin expressionand mechanisms of reversing drug-resistance of human lungadenocarcinoma cells by siRNA. Chinese Medical Journal 2010;123: 2901-2907.
260. Dan HC, Sun M, Kaneko S, et al. Akt phosphorylation andstabilization of X-linked inhibitor of apoptosis protein (XIAP). JBiological Chem 2004; 279: 5405-5412.
261. Zhang YC, Wang Y, Gao WX, et al. Transfer of siRNA againstXIAP induces apoptosis and reduces tumor cells growth potentialin human breast cancer in vitro and in vivo. Breast Cancer Researchand Treatment 2006; 96: 267-277.
262. Chen Y, Bathula SR, Yang Q, Huang L. Targeted nanoparticlesdeliver siRNA to melanoma. J Invest Dermatol 2010; 130: 2790-2798.
263. Wang YH, Liu S, Zhang G, et al. Knockdown of c-Myc expressionby RNAi inhibits MCF-7 breast tumor cells growth in vitro and invivo. Breast Cancer Research 2005; 7: R220-R228.
264. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo deliveryof small interfering RNAs via cell-surface receptors. NatBiotechnol 2005; 23: 709-717.
265. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modifiedwith tumor-targeting scFv deliver siRNA and miRNA for cancertherapy. Mol Ther 2010; 18: 1650-1656.
266. Chen Y, Wu JJ, Huang L. Nanoparticles targeted with NGR motifdeliver c-myc siRNA and doxorubicin for anticancer therapy. MolTher 2010; 18: 828-834.
267. Choudhury A, Charo J, Parapuram SK, et al. Small interferingRNA (siRNA) inhibits the expression of the Her2/neu gene,upregulates HLA class I and induces apoptosis of Her2/neupositive tumor cell lines. Int J Cancer 2004; 108: 71-77.
268. Liu XQ, Lei M, Erikson RL. Normal cells, but not cancer cells,survive severe Plk1 depletion. Molecular and Cellular Biology 2006; 26: 2093-108.
269. Degenhardt Y, Lampkin T. Targeting Polo-like kinase in cancertherapy. Clin Cancer Res 2010; 16: 384-389.
270. Shi W, Alajez NM, Bastianutto C, et al. Significance of Plk1regulation by miR-100 in human nasopharyngeal cancer. International J Cancer 2010; 126: 2036-2048.
271. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K.Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosisand spindle formation in human cancer cells. J Natl Cancer Inst 2002; 94: 1863-1877.
272. Benoit DSW, Henry SM, Shubin AD, Hoffman AS, Stayton PS.pH-Responsive Polymeric siRNA Carriers Sensitize MultidrugResistant Ovarian Cancer Cells to Doxorubicin via Knockdown ofPolo-like Kinase 1. Molecular Pharmaceutics 2010; 7: 442-455.
273. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003; 22: 7512-7523.
274. Shen DW, Goldenberg S, Pastan I, Gottesman MM. Decreasedaccumulation of [14C]carboplatin in human cisplatin-resistant cellsresults from reduced energy-dependent uptake. J Cell Physiol 2000;183: 108-116.
275. Shen D, Pastan I, Gottesman MM. Cross-resistance to methotrexateand metals in human cisplatin-resistant cell lines results from apleiotropic defect in accumulation of these compounds associatedwith reduced plasma membrane binding proteins. Cancer Research 1998; 58: 268-275.
276. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I,Gottesman MM. Biochemical, cellular, and pharmacologicalaspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-398.
277. Lehne G. P-glycoprotein as a drug target in the treatment ofmultidrug resistant cancer. Curr Drug Targets 2000; 1: 85-99.
278. Takakuwa O, Oguri T, Ozasa H, et al. Over-expression of MDR1in amrubicinol-resistant lung cancer cells. Cancer ChemotherPharmacol 2010.
279. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study ofbortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348: 2609-2617.
280. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib orhigh-dose dexamethasone for relapsed multiple myeloma. N Engl JMed 2005; 352: 2487-2498.
281. Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G, Wolf D. Knockdown of PgP resensitizes leukemic cells to proteasomeinhibitors. Biochem Biophys Res Commun 2007; 361: 549-554.
282. Singhal SS, Sehrawat A, Sahu M, et al. Rlip76 transports sunitiniband sorafenib and mediates drug resistance in kidney cancer. International J Cancer 2010; 126: 1327-1338.
283. Singhal SS, Wickramarachchi D, Singhal J, Yadav S, Awasthi YC, Awasthi S. Determinants of differential doxorubicin sensitivitybetween SCLC and NSCLC. FEBS Lett 2006; 580: 2258-2264.
284. Singhal SS, Yadav S, Singhal J, Zajac E, Awasthi YC, Awasthi S. Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. Biochem Pharmacol 2005; 70: 481-488.
285. Vatsyayan R, Lelsani PC, Awasthi S, Singhal SS. RLIP76: aversatile transporter and an emerging target for cancer therapy. Biochem Pharmacol 2010; 79: 1699-1705.
286. Singhal SS, Roth C, Leake K, Singhal J, Yadav S, Awasthi S. Regression of prostate cancer xenografts by RLIP76 depletion. Biochem Pharmacol 2009; 77: 1074-1083.
287. Awasthi YC, Sharma R, Yadav S, Dwivedi S, Sharma A, AwasthiS. The non-ABC drug transporter RLIP76 (RALBP-1) plays amajor role in the mechanisms of drug resistance. Curr Drug Metab 2007; 8: 315-323.
288. Singhal SS, Awasthi YC, Awasthi S. Regression of melanoma in amurine model by RLIP76 depletion. Cancer Research 2006; 66:2354-2360.
289. Singhal SS, Singhal J, Yadav S, Sahu M, Awasthi YC, Awasthi S.RLIP76: a target for kidney cancer therapy. Cancer Research 2009;69: 4244-4251.
290. Calcabrini A, Meschini S, Stringaro A, Cianfriglia M, Arancia G, Molinari A. Detection of P-glycoprotein in the nuclear envelope ofmultidrug resistant cells. Histochem J 2000; 32: 599-606.
291. Gervasoni JE, Jr., Fields SZ, Krishna S, et al. Subcellulardistribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocalmicroscopy. Cancer Research 1991; 51: 4955-4963.
292. Puhlmann U, Ziemann C, Ruedell G, et al. Impact of thecyclooxygenase system on doxorubicin-induced functionalmultidrug resistance 1 overexpression and doxorubicin sensitivityin acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther 2005; 312: 346-354.
293. von Bueren AO, Shalaby T, Oehler-Janne C, et al. RNAinterference-mediated c-MYC inhibition prevents cell growth anddecreases sensitivity to radio- and chemotherapy in childhoodmedulloblastoma cells. BMC Cancer 2009; 9: 10.
294. Link KH, Gansauge F, Pillasch J, Beger HG. Multimodal therapiesin ductal pancreatic cancer. The future. Int J Pancreatol 1997; 21:71-83.
295. Link KH, Leder G, Pillasch J, et al. In vitro concentration responsestudies and in vitro phase II tests as the experimental basis forregional chemotherapeutic protocols. Semin Surg Oncol 1998; 14:189-201.
296. Warenius HM, Seabra LA, Maw P. Sensitivity to cisdiamminedichloroplatinumin human cancer cells is related toexpression of cyclin D1 but not c-raf-1 protein. International JCancer 1996; 67: 224-231.
297. Rhee K, Bresnahan W, Hirai A, Hirai M, Thompson EA. c-Mycand cyclin D3 (CcnD3) genes are independent targets forglucocorticoid inhibition of lymphoid cell proliferation. CancerResearch 1995; 55: 4188-4195.
298. Tan A, Bitterman P, Sonenberg N, Peterson M, Polunovsky V. Inhibition of Myc-dependent apoptosis by eukaryotic translationinitiation factor 4E requires cyclin D1. Oncogene 2000; 19: 1437-1447.
299. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. Theprosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptionaltarget of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13: 382-387.
300. Wang CY, Guttridge DC, Mayo MW, Baldwin AS, Jr. NF-kappaBinduces expression of the Bcl-2 homologue A1/Bfl-1 topreferentially suppress chemotherapy-induced apoptosis. Mol CellBiol 1999; 19: 5923-5929.
301. Biliran H, Jr., Banerjee S, Thakur A, et al. c-Myc-inducedchemosensitization is mediated by suppression of cyclin D1expression and nuclear factor-kappa B activity in pancreatic cancercells. Clin Cancer Res 2007; 13: 2811-2821.
302. An J, Xu QZ, Sui JL, Bai B, Zhou PK. Downregulation of c-mycprotein by siRNA-mediated silencing of DNA-PKcs in HeLa cells. International J Cancer 2005; 117: 531-7.
303. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor ofBcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-81.
304. Holinger EP, Chittenden T, Lutz RJ. Bak BH3 peptides antagonizeBcl-xL function and induce apoptosis through cytochrome cindependentactivation of caspases. J Biological Chem 1999; 274:13298-304.
305. Shangary S, Oliver CL, Tillman TS, Cascio M, Johnson DE.Sequence and helicity requirements for the proapoptotic activity ofBax BH3 peptides. Mol Cancer Ther 2004; 3: 1343-1354.
306. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently inducesapoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10: 389-399.
307. Xu YM, Wang LF, Jia LT, et al. A caspase-6 and anti-humanepidermal growth factor receptor-2 (HER2) antibody chimericmolecule suppresses the growth of HER2-overexpressing tumors. JImmunol 2004; 173: 61-67.
308. Wang LF, Zhou Y, Xu YM, et al. A caspase-6 and anti-HER2antibody chimeric tumor-targeted proapoptotic molecule decreasedmetastasis of human osteosarcoma. Cancer Invest 2009; 27: 774-780.
309. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonistsfor cancer therapy. Nat Rev Drug Discov 2008; 7: 989-1000.
310. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent andorally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68:3421-3428.
311. Shangary S, Johnson DE. Peptides Derived from BH3 Domains ofBcl-2 Family Members:≠A Comparative Analysis of Inhibitionof Bcl-2, Bcl-xL and Bax Oligomerization, Induction ofCytochrome c Release, and Activation of Cell Deathâ BioChem 2002; 41: 9485-9495.
312. Finnegan NM, Curtin JF, Prevost G, Morgan B, Cotter TG. Induction of apoptosis in prostate carcinoma cells by BH3 peptideswhich inhibit Bak/Bcl-2 interactions. Br J Cancer 2001; 85: 115-121.
313. Li N, Lin P, Cai C, Pan Z, Weisleder N, Ma J. The amino-terminalpeptide of Bax perturbs intracellular Ca2+ homeostasis to enhanceapoptosis in prostate cancer cells. Am J Physiol Cell Physiol 2009;296: C267-C272.
314. Dharap SS, Minko T. Targeted proapoptotic LHRH-BH3 peptide.Pharmaceutical Research 2003; 20: 889-896.
315. Li B, Zhang LJ, Zhang ZL, et al. Synergistic tumor growthinhibitoryeffect of the prostate-specific antigen-activated fusionpeptide BSD352 for prostate cancer therapy. Anticancer Drugs 2010.
316. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity oftargeted pro-apoptotic peptides. Nat Med 1999; 5: 1032-1038.
317. Shamay Y, Adar L, Ashkenasy G, David A. Light induced drugdelivery into cancer cells. Biomaterials 2011; 32: 1377-86.
318. Moellering RE, Cornejo M, Davis TN, et al. Direct inhibition ofthe NOTCH transcription factor complex. Nature 2009; 462: 182-188.
319. Stewart ML, Fire E, Keating AE, Walensky LD. The MCL-1 BH3helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nature Chemical Biology 2010; 6: 595-601.
320. Lopes LB, Furnish E, Komalavilas P, et al. Enhanced skinpenetration of P20 phosphopeptide using protein transductiondomains. European J Pharmaceutics and Biopharmaceutics 2008;68: 441-445.
321. Elliott G, O'Hare P. Intercellular trafficking and protein delivery bya herpesvirus structural protein. Cell 1997; 88: 223-233.
322. Kokryakov VN, Harwig SS, Panyutich EA, et al. Protegrins:leukocyte antimicrobial peptides that combine features ofcorticostatic defensins and tachyplesins. FEBS Lett 1993; 327:231-236.
323. Mudhakir D, Akita H, Tan E, Harashima H. A novel IRQ ligandmodifiednano-carrier targeted to a unique pathway of caveolarendocytic pathway. J Controlled Release 2008; 125: 164-173.
324. Jans DA. Nuclear signaling pathways for polypeptide ligands andtheir membrane receptors? FASEB J 1994; 8: 841-847.
325. Alshamsan A, Hamdy S, Samuel J, El-Kadi AO, Lavasanifar A, Uludag H. The induction of tumor apoptosis in B16 melanomafollowing STAT3 siRNA delivery with a lipid-substitutedpolyethylenimine. Biomaterials 2010; 31: 1420-1428.
326. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy bytumor selective delivery with ligand-targeted sterically stabilizednanoparticle. Nucleic Acids Res 2004; 32: e149.
327. Liu XX, Rocchi P, Qu FQ, et al. PAMAM dendrimers mediatesiRNA delivery to target Hsp27 and produce potentantiproliferative effects on prostate cancer cells. ChemMedChem 2009; 4: 1302-1310.
328. Yadav S, van Vlerken LE, Little SR, Amiji MM. Evaluations of combination MDR-1 gene silencing and paclitaxel administrationin biodegradable polymeric nanoparticle formulations to overcomemultidrug resistance in cancer cells. Cancer Chemother Pharmacol 2009; 63: 711-722.
329. Varkouhi AK, Lammers T, Schiffelers RM, van Steenbergen MJ, Hennink WE, Storm G. Gene silencing activity of siRNApolyplexes based on biodegradable polymers. Eur J PharmBiopharm 2010.
330. Lee WR, Shen SC, Lai HH, Hu CH, Fang JY. Transdermal drugdelivery enhanced and controlled by erbium:YAG laser: acomparative study of lipophilic and hydrophilic drugs. J ControlRelease 2001; 75: 155-166.
331. Grzmil M, Thelen P, Hemmerlein B, et al. Bax inhibitor-1 isoverexpressed in prostate cancer and its specific down-regulationby RNA interference leads to cell death in human prostatecarcinoma cells. American J Pathology 2003; 163: 543-552.
332. Crnkovic-Mertens I, Hoppe-Seyler F, Butz K. Induction ofapoptosis in tumor cells by siRNA-mediated silencing of thelivin/ML-IAP/KIAP gene. Oncogene 2003; 22: 8330-8336.
333. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogeneefficiently kills human papillomavirus-positive cancer cells. Oncogene 2003; 22: 5938-5945.
334. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Shortinterfering RNA (siRNA) targeting the Lyn kinase inducesapoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemiacells. Nature Medicine 2004; 10: 1187-1189.
335. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion inducesapoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100:5789-5794.
336. Troussard AA, Mawji NM, Ong C, Mui A, St Arnaud R, Dedhar S. Conditional knock-out of integrin-linked kinase demonstrates anessential role in protein kinase B/Akt activation. J Biological Chem 2003; 278: 22374-22378.
337. Glaser KB, Li JL, Staver MJ, Wei RQ, Albert DH, Davidsen SK. Role of Class I and Class II histone deacetylases in carcinoma cellsusing siRNA. Biochemical and Biophysical ResearchCommunications 2003; 310: 529-536.
338. Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is atherapeutic target in melanoma. Oncogene 2004; 23: 6292-6298.
339. Olichon A, Baricault L, Gas N, et al. Loss of OPA1 perturbates themitochondrial inner membrane structure and integrity, leading tocytochrome c release and apoptosis. J Biological Chem 2003; 278:7743-7746.
340. Wilda M, Fuchs U, Wossmann W, Borkhardt A. Killing ofleukemic cells with a BCR/ABL fusion gene by RNA interference(RNAi). Oncogene 2002; 21: 5716-5724.
341. Lee GH, Yan C, Shin SJ, et al. BAX inhibitor-1 enhances cancermetastasis by altering glucose metabolism and activating thesodium-hydrogen exchanger: the alteration of mitochondrialfunction. Oncogene 2010; 29: 2130-2141.
342. Amarzguioui M, Peng Q, Wiiger MT, et al. Ex vivo and in vivodelivery of anti-tissue factor short interfering RNA inhibits mousepulmonary metastasis of B16 melanoma cells. Clin Cancer Res 2006; 12: 4055-4061.
343. Villares GJ, Zigler M, Wang H, et al. Targeting melanoma growthand metastasis with systemic delivery of liposome-incorporatedprotease-activated receptor-1 small interfering RNA. Cancer Res 2008; 68: 9078-9086.
344. Liu Y, Tao J, Li Y, et al. Targeting hypoxia-inducible factor-1alphawith Tf-PEI-shRNA complex via transferrin receptor-mediatedendocytosis inhibits melanoma growth. Mol Ther 2009; 17: 269-277.
345. Hua J, Chen DQ, Fu H, et al. Short hairpin RNA-mediatedinhibition of S100A4 promotes apoptosis and suppressesproliferation of BGC823 gastric cancer cells in vitro and in vivo. Cancer Letters 2010; 292: 41-47.
346. Zamora-Avila DE, Zapata-Benavides P, Franco-Molina MA, et al. WT1 gene silencing by aerosol delivery of PEI-RNAi complexesinhibits B16-F10 lung metastases growth. Cancer Gene Ther 2009;16: 892-899.
347. Moschos SA, Jones SW, Perry MM, et al. Lung delivery studiesusing siRNA conjugated to TAT(48-60) and penetratin revealpeptide induced reduction in gene expression and induction ofinnate immunity. Bioconjug Chem 2007; 18: 1450-1459.
348. Turner JJ, Jones S, Fabani MM, Ivanova G, Arzumanov AA, GaitMJ. RNA targeting with peptide conjugates of oligonucleotides,siRNA and PNA. Blood Cells Mol Dis 2007; 38: 1-7.
349. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. Asmall interfering RNA targeting vascular endothelial growth factoras cancer therapeutics. Cancer Research 2004; 64: 3365-3370.
350. Zhao Y, Zhao L, Zhou L, et al. Quantum dot conjugates fortargeted silencing of bcr/abl gene by RNA interference in humanmyelogenous leukemia K562 cells. J Nanosci Nanotechnol 2010;10: 5137-5143.
351. Kumar M, Yigit M, Dai G, Moore A, Medarova Z. Image-guidedbreast tumor therapy using a small interfering RNA nanodrug. Cancer Research 2010; 70: 7553-61.